TICKERNOMICS Sign up
Last Update: 2024-12-27 15:30:50
Avicanna Inc ( AVCN.TO ) https://www.avicanna.com
0.22USD
Sector:
Healthcare
Industry:
Drug Manufacturers-Specialty & Generic
Country:
Canada
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-15.78%
AVCN.TO
SPY
32.66%
-67.94%
AVCN.TO
SPY
108.59%
-89.55%
AVCN.TO
SPY
302.52%
AVCN.TO
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
21.15
20.79
0.00
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-4.34
1.14
3.63
-1.52
0.00
-5.63
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-28.68
44.05
-20.01
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
12.7472
-47.99
-71.62
2.29
Other Earnings and Cash Flow Stats:
Avicanna Inc ( AVCN.TO ) Net Income TTM ($MM) is -4.87
Avicanna Inc ( AVCN.TO ) Operating Income TTM ($MM) is -4.35
Avicanna Inc ( AVCN.TO ) Owners' Earnings Annual ($MM) is 0.00
Avicanna Inc ( AVCN.TO ) Current Price to Owners' Earnings ratio is 0.00
Avicanna Inc ( AVCN.TO ) EBITDA TTM ($MM) is -3.67
Avicanna Inc ( AVCN.TO ) EBITDA Margin is -20.01%
Capital Allocation:
Avicanna Inc ( AVCN.TO ) has paid 0.00 dividends per share and bought back -6.591814 million shares in the past 12 months
Avicanna Inc ( AVCN.TO ) has reduced its debt by 1.6912053009551 million USD in the last 12 months
Capital Structure:
Avicanna Inc ( AVCN.TO ) Interest-bearing Debt ($MM) as of last quarter is 0
Avicanna Inc ( AVCN.TO ) Annual Working Capital Investments ($MM) are 0
Avicanna Inc ( AVCN.TO ) Book Value ($MM) as of last quarter is 5
Avicanna Inc ( AVCN.TO ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
Avicanna Inc ( AVCN.TO ) has 0 million in cash on hand as of last quarter
Avicanna Inc ( AVCN.TO ) has 7 million of liabilities due within 12 months, and long term debt 1 as of last quarter
Avicanna Inc ( AVCN.TO ) has 93 common shares outstanding as of last quarter
Avicanna Inc ( AVCN.TO ) has 0 million USD of preferred stock value
Academic Scores:
Avicanna Inc ( AVCN.TO ) Altman Z-Score is -5.70 as of last quarter
Avicanna Inc ( AVCN.TO ) Piotroski Score is 5.00 as of last quarter
Corporate Governance:
Avicanna Inc ( AVCN.TO ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Avicanna Inc ( AVCN.TO ) for the amount of $ on
16.98% of Avicanna Inc ( AVCN.TO ) is held by insiders, and 0.00% is held by institutions
Avicanna Inc ( AVCN.TO ) went public on 1970-01-01
Other Avicanna Inc ( AVCN.TO ) financial metrics:
FCF:-0.40
Unlevered Free Cash Flow:0.00
EPS:-0.06
Operating Margin:-28.68
Gross Profit Margin:44.05
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-20911.34
Beta:2.29
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Avicanna Inc ( AVCN.TO ) :
Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research and development of evidence-based products for consumer medical and pharmaceutical segments worldwide. The company collaborates with Canadian academic and medical institutions. Its scientific platform includes research and development, and clinical development that leads to the commercialization of approximately twenty products across four main market segments. The company provides medical and wellness products containing cannabidiol, cannabigerol, and tetrahydrocannabinol under the RHO Phyto brand; functional CBD consumer derma-cosmetic and topical products under the Pura H&W and Pura Earth brand names; and cannabis dried flowers, standardized seeds, full spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations derived from hemp and cannabis cultivars under the Aureus brand. It also develops pharmaceutical products for epidermolysis bullosa, dermatology, chronic pain, and various neurological disorders. The company has research collaboration with Dr. Christine Allen'sResearch Group for the development of a cannabinoid-based treatment for lung inflammation associated with COVID19. Avicanna Inc. was incorporated in 2016 and is headquartered in Toronto, Canada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.